Article Text

Download PDFPDF

1509-F TFEB activation in mediastinal lymph nodes: a potential modulator of immune response in NSCLC
  1. Ines Mota1 and
  2. Laura Santambrogio2
  1. 1Weill Cornell Medicine, New York, NY, USA
  2. 2Weill-Cornell Medical College, New York, NY, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths worldwide.1 Despite the promise shown by immune checkpoint inhibitors (ICIs) in enhancing survival and tumor control for a subset of patients, a significant portion remains non-responsive, which may be attributed to a deficiency in CD8 T-cell tumor infiltration. The presence of pre-existing tumor-reactive T-cell infiltration is, in fact, a crucial determinant of ICI efficacy. Interestingly, despite NSCLC tumors with KRAS and TP53 mutations showcasing pronounced T-cell infiltration, ICI response rates stand at about 35%, pointing to varied tumor-reactive T-cell functionalities. This inconsistency suggests that the functional states of tumor-reactive T-cells vary considerably among patients. Central to these challenges is the immunosuppressive milieu of the lung tumor microenvironment that can be attributed to impaired peptide presentation in the tumor-draining lymph nodes together with a persistent IFN-γ activation signature.2–6

Methods and Results In this study, we spotlight the role of transcription factor EB (TFEB), crucial for autophagy and MHC-II peptide presentation.7 Specifically, TFEB exhibited consistent overexpression in lung tissue-draining mediastinal lymph nodes, contrasting other lymphatic regions. Notably, overexpressing TFEB in CD11c+ dendritic cells augmented tumor-specific CD4 T-cell responses, yet reduced CD8 T-cell activities, suggesting a potential shift towards a tolerogenic immune environment in NSCLC.

Conclusions Conclusively, our insights into TFEB’s function in NSCLC highlight the complex relationship between tissue-specific elements and tumor immunogenicity, offering avenues for refining immunotherapeutic strategies.


  1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73 (1):17–48. DOI: 10.3322/caac.21763.

  2. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553 (7689):446–454. DOI: 10.1038/nature25183.

  3. Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489 (7417):519–525. DOI: 10.1038/nature11404.

  4. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn MJ, Eder JP, Balmanoukian AS, Aggarwal C, Horn L, et al. Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J Clin Oncol 2019; 37 (28):2518–2527. DOI: 10.1200/JCO.19.00934.

  5. Horton BL, Morgan DM, Momin N, Zagorulya M, Torres-Mejia E, Bhandarkar V, Wittrup KD, Love JC, Spranger S. Lack of CD8+ T cell effector differentiation during priming mediates checkpoint blockade resistance in non-small cell lung cancer. Sci Immunol 2021; 6 (64):eabi8800. DOI: 10.1126/sciimmunol.abi8800.

  6. Zagorulya M, Yim L, Morgan DM, Edwards A, Torres-Mejia E, Momin N, McCreery CV, Zamora IL, Horton BL, Fox JG, et al. Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer. Immunity 2023; 56 (2):386–405.e310. DOI: 10.1016/j.immuni.2023.01.010.

  7. Samie M, Cresswell P. The transcription factor TFEB acts as a molecular switch that regulates exogenous antigen-presentation pathways. Nat Immunol 2015; 16 (7):729–736. DOI: 10.1038/ni.3196.

Ethics Approval The mouse protocol has been approved by Weill Cornell Medicine committee: 2020-0017

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.